AMENDMENT NO. 1Manufacturing, Commercialization and Development Agreement • August 9th, 2007 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 1 (the “Amendment”) amends the MANUFACTURING, COMMERCIALIZATION AND DEVELOPMENT AGREEMENT (the “Agreement”) entered into as of July 31, 2006 between ISIS PHARMACEUTICALS, INC., a Delaware corporation, through its IBIS BIOSCIENCES division (“Ibis”), and BRUKER DALTONICS INC., a Delaware corporation (“Bruker”) and is effective on the date both parties have signed below.
COLLABORATION AND LICENSE AGREEMENT between ISIS PHARMACEUTICALS, INC. and BRISTOL-MYERS SQUIBB COMPANYCollaboration and License Agreement • August 9th, 2007 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into effective as of May 8, 2007 (the “Effective Date”), by and between Bristol-Myers Squibb Company, a Delaware Corporation (“BMS”) and Isis Pharmaceuticals, Inc., a Delaware Corporation (“Isis”). BMS and Isis each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
